Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 Prime and Deferred-Booster Dosing Schedule in 9-11 Year-Olds
NCT02568566Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by National Cancer Institute. Started May 2016; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT02568566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568566.